Plain-English translation of NCT05643651 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Kawasaki Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing rivaroxaban, a newer type of blood thinner, in children over 2 years old who have developed giant aneurysms (enlarged areas) in their coronary arteries as a complication of Kawasaki disease. Currently, these children must take — an older blood thinner that requires frequent blood tests — for life. Researchers want to see if rivaroxaban could be easier for families to manage while keeping children safe from dangerous blood clots.
Children with giant coronary aneurysms after Kawasaki disease need lifelong blood-thinning treatment, but is hard for families to manage because it requires monthly blood tests and careful monitoring. This medication might offer a simpler, more convenient option that still protects against life-threatening clots.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new medication (rivaroxaban) or the standard treatment (), both combined with an antiplatelet drug like . The study lasts 3 months, during which you'll take your assigned medication daily by mouth. If assigned to , you'll have blood tests once a month to check that your blood levels are in the right range. Researchers will track your progress, watch for any bleeding or side effects, and monitor how well the medication is working.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
China